Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140

Author: Benzinga Newsdesk | May 16, 2024 12:00pm
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price target from $116 to $140.

Posted In: ASND